Breast Cancer Coverage from Every Angle

Michael Gnant, MD: Perspective on Negative Findings With Palbociclib in HR+/HER2– Early Breast Cancer

Posted: Monday, January 17, 2022

Michael Gnant, MD, of the Medical University of Vienna, discusses the clinical implications of negative findings from the PALLAS trial, which showed that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival for patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer and whether any correlative studies hint at patient subgroups that this regimen may benefit.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.